U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS

Market Challenges And Opportunities

Approvals from Regulatory Authorities

Increasing product approvals from the regulatory authorities for the intravenous immunoglobulins is expected to provide lucrative growth opportunities for players in the U.S. intravenous immunoglobulin market. For instance, on May 20, 2020, the U.S. Food and Drug Administration (FDA) approved an investigational new drug (IND) application submitted by Octapharma U.S., one of the largest human protein product manufacturers, for a phase three clinical trial on the efficacy and safety of Octagam 10 percent [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression.

Growth Drivers

• Increasing cases of Kawasaki disease
• Increasing product launches and approvals 

Opportunities

The increasing cases of Kawasaki disease for which intravenous immunoglobulins are used as a treatment, is expected to drive growth of the market over the forecast period.

The emerging prevalence of Kawasaki disease is expected to bolster the growth of the U.S. intravenous immunoglobulin market. Kawasaki disease (KD), also known as Kawasaki syndrome, is an unknown etiology acute febrile illness that primarily affects children under the age of five. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2016, about 5440 hospitalizations for KD were reported among children under the age of 18 in the U.S.; 3935 of these children were under the age of five, resulting in a hospitalization rate of 19.8 per 100,000 children in that age group.